The Leapfrog Group today released its spring 2026 Hospital Safety Grade. The biannual Safety Grade is an "A," "B," "C," "D" or "F" assigned to most general hospitals in the United States based on ...

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") , a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a ...

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic ...

Stroke drug developer Argenica Therapeutics plans a second trial to test its novel candidate, in a sector that has few ...

Conference Call and Webcast Today at 8:30 a.m. ETPositive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) ...

If the nuclear issue is sealed through an incomplete agreement, the Islamic government's enduring nuclear ambitions are ...

Ahead of the election, the Southern California News Group compiled a list of questions to pose to the candidates vying to ...

Lastly, a broader view of clinical outcomes and operational insights is a cornerstone to product value translation. Gathering ...

After graduating at the top of her class at Sachem East High School in 2016, Mazza, 28, completed her undergraduate work at ...

Formulation development serves as a vital bridge between a drug substance and a drug product that will remain stable and ...

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on tra ...